Biblio
“Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-analysis.”, JAMA Netw Open, vol. 3, no. 1, p. e1918939, 2020.
, “Cervical cancer in Eastern Europe: review and proceedings from the Cervical Cancer Research Conference.”, Int J Gynecol Cancer, 2020.
, “Expectations and preferences of patients with primary and relapsed ovarian cancer to maintenance therapy: A NOGGO/ENGOT-ov22 and GCIG survey (Expression IV).”, Int J Gynecol Cancer, vol. 30, no. 4, pp. 509-514, 2020.
, “Fertility-sparing treatment for intramucous, moderately differentiated, endometrioid endometrial cancer: a Gynecologic Cancer Inter-Group (GCIG) study”, Journal of Gynecologic Oncology, vol. 31, 2020.
, “A GCIG international survey: clinical practice patterns of sentinel lymph node biopsies in cervical cancer.”, Arch Gynecol Obstet, 2019.
, , ,
“Adjuvant therapy for women with high-risk endometrial carcinoma.”, Lancet Oncol, 2018.
, “Advancing clinical research globally: Cervical cancer research network from Mexico.”, Gynecol Oncol Rep, vol. 25, pp. 90-93, 2018.
, “Commonly Occurring Cell Subsets in High-Grade Serous Ovarian Tumors Identified by Single-Cell Mass Cytometry.”, Cell Rep, vol. 22, no. 7, pp. 1875-1888, 2018.
, “Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial.”, Ann Oncol, vol. 29, no. 3, pp. 737-743, 2018.
, “Too many women are dying from cervix cancer: Problems and solutions.”, Gynecol Oncol, 2018.
, “Cervical cancer: A global health crisis.”, Cancer, vol. 123, no. 13, pp. 2404-2412, 2017.
, “Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference.”, Ann Oncol, vol. 28, no. suppl_8, pp. viii30-viii35, 2017.
, , “Advances and Concepts in Cervical Cancer Trials: A Road Map for the Future.”, Int J Gynecol Cancer, vol. 26, no. 1, p. 207, 2016.
, “BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.”, Gynecol Oncol, vol. 140, no. 3, pp. 443-9, 2016.
, “Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.”, Lancet, vol. 387, no. 10023, pp. 1066-74, 2016.
, “Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study.”, BMC Med Ethics, vol. 17, no. 1, p. 63, 2016.
, “Fertility preservation: A key survivorship issue for young women with cancer ”, Frontiers in Oncology , vol. 6, no. 102, 2016.
, “Germline BRCA1/2 testing practices in ovarian cancer: Current state and opportunities for new directions.”, Gynecol Oncol, vol. 140, no. 1, p. 94, 2016.
, “Ovarian Cancer and BRCA1/2 Testing: Opportunities to improve clinical care and disease prevention ”, Frontiers in Oncology , vol. 6, no. 00119 , 2016.
, “Practice patterns of adjuvant therapy for intermediate/high recurrence risk cervical cancer patients in Japan.”, J Gynecol Oncol, vol. 27, no. 3, p. e29, 2016.
, “Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group.”, Int J Clin Oncol, vol. 21, no. 1, pp. 168-76, 2016.
, “Randomized study of sequential cisplatin-topotecan/carboplatin-paclitaxel versus carboplatin-paclitaxel: effects on quality of life.”, Support Care Cancer, vol. 24, no. 3, p. 1249, 2016.
,